Guidelines for ATC classification and DDD assignment - WHOCC

J05AC Cyclic amines
178
Amantadine is classified in N04 - Anti-Parkinson drugs.
J05AD Phosphonic acid derivatives
The DDD for foscarnet is based on the treatment of CMV-retinitis in
AIDS patients.
J05AE Protease inhibitors
Ritonavir added as a pharmacokinetic enhancer is allowed in J05AE06
Lopinavir.
The DDDs are based on combination therapy in HIV infections.
The DDDs for atazanavir, fosamprenavir and lopinavir are based on
combination therapy with ritonavir as a pharmacokinetic enhancer.
The DDD for saquinavir is based on the dose recommendations for
hard capsules.
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
The DDDs are based on combination therapy in HIV infections.
The DDD for tenofovir disoproxil is 245 mg and is equivalent to
300 mg tenofovir disoproxil fumarat.
The DDDs for entecavir and telbivudine are based on monotherapy
in the treatment of chronic hepatitis B virus infections.
J05AG Non-nucleoside reverse transcriptase inhibitors
The DDDs are based on combination therapy in HIV infections.
J05AH Neuraminidase inhibitors
All neuraminidase inhibitors are classified here, regardless of
formulation.